MHRA 2030 Strategy: Recognition, Reliance and the Future of AI Devices

1. Key takeaways

The MHRA 2030 Strategy was published on 14 October 2026. One of its core directions is to expand recognition and reliance pathways with trusted regulators in order to reduce regulatory burden, strengthen supply resilience and support timely patient access. The decision on indefinite recognition of CE marking taken on 21 October 2026 is the first major implementation of this strategic direction. AI medical devices, for their part, are listed as a priority for a future licencing route to be built under authorisation from primary legislation.

The sequence of these dates is instructive: the strategy first, the concrete decision one week later. It shows the agency operating on a published plan rather than improvising, and it gives manufacturers a reasonably reliable method for anticipating what comes next — measures that reduce duplicative review and improve supply resilience are the ones most likely to advance first. For AI and software developers specifically, the message is twofold: today’s pathway remains the established one, and a genuinely new licencing architecture is being prepared that will not simply amend the existing rules. Both messages should shape investment decisions now, because development timelines in this sector routinely outlast legislative ones.

2. Legal basis

• MHRA 2030 Strategy (GOV.UK publication, published 14 October 2026).
• GOV.UK news announcement — Government confirms indefinite recognition of CE marked medical devices (21 October 2026): links the indefinite recognition to the expansion of the recognition and reliance pathways under the 2030 Strategy; and states that primary legislation will be sought to develop a future licencing route for software and AI devices, reflecting the recommendations of the National Commission into the Regulation of AI in Healthcare.
• Text currently in force: UK MDR 2002 (SI 2002/618, as amended) — there are no separate dedicated rules for AI devices; the general rules apply according to the definitions in reg 2 and the classification rules in reg 7.

3. Expert insights

Insight one: a strategy document is not law, but it is a strong directional signal. The 2030 Strategy does not change any company’s obligations by itself, but it reveals the preferences that future legislation will likely follow — any pathway that reduces duplicative review and strengthens supply resilience will be advanced as a priority. When making long-cycle investment decisions, companies should incorporate this preference into their scenario analysis, weighting those options that align with it, because early alignment tends to mean earlier benefit when the instruments eventually take effect.

Insight two: the terms recognition and reliance must be strictly distinguished. The UK consultation documents draw on the World Health Organization definitions: recognition is the acceptance of the regulatory decision of another regulator or trusted institution, requiring evidence that the reference regulator’s requirements are sufficient to meet those of the adopting regulator; reliance is the situation where the adopting regulator gives significant weight to the assessments or authoritative information of another body in its own decision, while remaining independent, responsible and accountable. The current UK approach to CE marking is in substance recognition. Using the two terms interchangeably in internal documents and customer communications invites confusion about what the UK actually accepts from other jurisdictions.

Insight three: the regulatory form for AI devices may go beyond device rules as such. The official wording refers to a future licencing route, rather than patching the existing UK MDR 2002 framework. If implemented, AI devices could face a separate access mechanism running in parallel with the existing conformity assessment. That would affect not only regulatory strategy but also product lifecycle planning, since a parallel mechanism implies its own submission content, review rhythm and change-control expectations that do not map one-to-one onto today’s conformity assessment files.

Insight four: the strategy frames the purpose of the reforms in supply terms. The stated aims — reducing regulatory burden, strengthening supply resilience and supporting timely patient access — explain why recognition and reliance are the chosen instruments: they reuse the assessments of trusted regulators instead of duplicating them. For manufacturers, this framing is useful in two ways. It identifies which future measures are likely to move first, and it provides the vocabulary for reading the reforms that follow: measures consistent with those aims can be expected to progress, while measures that add review burden without a resilience rationale can be expected to wait. Screening each new announcement against this test keeps the monitoring ledger focused on what actually changes the compliance picture.

4. Practical recommendations

GRZAN recommends that AI and software device companies complete compliance under the current rules first (establish characterisation and classification under reg 2 and reg 7, and build the PMS system under Part 4A), while establishing a record system for algorithm changes and performance monitoring — under a future licencing route this data is highly likely to become core submission material. Version control that documents each model change, its rationale, its validation evidence and its deployment dates will be directly reusable if the new mechanism demands lifecycle evidence. The 2030 Strategy and the recommendations of the AI commission should be tracked quarterly, with findings logged in the regulatory monitoring ledger. As a practical estimate, companies that begin structured algorithm documentation now face a substantially smaller retrofit than those that wait for the future route to be defined, since the underlying records take months to reconstruct and cannot be recovered once development teams have moved on.

5. Verification checklist

• □ AI / software devices have been characterised and classified under the current rules
• □ A PMS system has been established under Part 4A
• □ A record system for algorithm versions and changes has been established
• □ Quarterly tracking of the 2030 Strategy and AI legislation progress has been established
• □ External materials do not present strategic direction as current obligation

Regulatory information verified as of 29 October 2026.

• Appointment of the UK Responsible Person (UKRP) and support with signing the letter of authorisation
• Full-process MHRA registration (DORS) filing and account lifecycle management
• Device classification determination, GMDN code selection and annual registration fee calculation
• Dual-route design for Great Britain and Northern Ireland, including UK(NI) solutions
• Establishment of post-market surveillance (PMS) systems, preparation of PMSR/PSUR and submission of vigilance reports
• Emergency handling of serious adverse incidents and field safety corrective actions (FSCA)
• Monitoring of UK regulatory changes and compliance gap assessment

For post-market compliance support in the UK market — vigilance reporting, recall management and MHRA inspection response — contact GRZAN at info@grzanglobal.com.